ESPR Esperion Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ESPR

Price (delayed)

$2.43

Market cap

$460.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$782.65M

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
ESPR's revenue has surged by 184% year-on-year and by 97% since the previous quarter
The company's gross profit has surged by 157% QoQ
The quick ratio has soared by 104% from the previous quarter but it has contracted by 18% YoY
Esperion Therapeutics's debt has increased by 7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.esperion.com
Peers: BMRN RARE LXRX FOLD

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
189.46M
Market cap
$460.39M
Enterprise value
$782.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.41
Earnings
Revenue
$229.74M
EBIT
-$27.89M
EBITDA
-$27.81M
Free cash flow
-$27.38M
Per share
EPS
-$0.97
Free cash flow per share
-$0.16
Book value per share
-$1.59
Revenue per share
$1.36
TBVPS
$2.2
Balance sheet
Total assets
$373.06M
Total liabilities
$667.36M
Debt
$548.87M
Equity
-$294.3M
Working capital
$201.09M
Liquidity
Debt to equity
-1.87
Current ratio
2.22
Quick ratio
1.71
Net debt/EBITDA
-11.59
Margins
EBITDA margin
-12.1%
Gross margin
81.9%
Net margin
-37.7%
Operating margin
-15.1%
Efficiency
Return on assets
-33.4%
Return on equity
N/A
Return on invested capital
-5.4%
Return on capital employed
-13.4%
Return on sales
-12.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
0%
1 week
1.67%
1 month
11.47%
1 year
71.13%
YTD
-18.73%
QTD
9.46%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$229.74M
Gross profit
$188.05M
Operating income
-$34.69M
Net income
-$86.51M
Gross margin
81.9%
Net margin
-37.7%
ESPR's revenue has surged by 184% year-on-year and by 97% since the previous quarter
The company's gross profit has surged by 157% QoQ
ESPR's operating margin has surged by 93% year-on-year and by 89% since the previous quarter
Esperion Therapeutics's net margin has surged by 87% YoY and by 79% QoQ

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.41
Esperion Therapeutics's EPS has surged by 71% YoY and by 52% QoQ
The equity has increased by 35% QoQ and by 11% YoY
ESPR's revenue has surged by 184% year-on-year and by 97% since the previous quarter
The price to sales (P/S) is 87% lower than the 5-year quarterly average of 13.8 and 6% lower than the last 4 quarters average of 1.9

Efficiency

How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has surged by 95% YoY and by 91% QoQ
The return on invested capital has surged by 84% year-on-year and by 82% since the previous quarter
The return on assets has surged by 64% since the previous quarter and by 61% year-on-year

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 44% less than the total liabilities
The quick ratio has soared by 104% from the previous quarter but it has contracted by 18% YoY
The total assets has soared by 81% from the previous quarter and by 48% YoY
ESPR's debt to equity has dropped by 57% since the previous quarter and by 20% year-on-year
The equity has increased by 35% QoQ and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.